Status:

COMPLETED

Itraconazole for the Prevention of Fungal Infections in Chronic Granulomatous Disease

Lead Sponsor:

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions:

Mycoses

Eligibility:

All Genders

Phase:

PHASE2

Brief Summary

This protocol describes a prospective, randomized study examining the safety and efficacy of Itraconazole for preventing fungal infections in patients with Chronic Granulomatous Disease (CGD). CGD is ...

Detailed Description

This protocol describes a prospective, randomized study examining the safety and efficacy of Itraconazole for preventing fungal infections in patients with Chronic Granulomatous Disease (CGD). CGD is ...

Eligibility Criteria

Documented chronic granulomatous disease more than 5 years of age.

No fungal infection within the past year.

Not currently on other antifungals or have taken other antifungals during the past 3 months.

Not currently on phenytoin or rifampin.

Negative pregnancy test within 2 weeks of starting protocol.

Key Trial Info

Start Date :

January 1 1991

Trial Type :

INTERVENTIONAL

End Date :

March 1 2001

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT00001280

Start Date

January 1 1991

End Date

March 1 2001

Last Update

March 4 2008

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

National Institute of Allergy and Infectious Diseases (NIAID)

Bethesda, Maryland, United States, 20892

Itraconazole for the Prevention of Fungal Infections in Chronic Granulomatous Disease | DecenTrialz